Central Banks Are Buying More Gold Than Ever-And This U.S. Miner Is Ready to Oblige
Central banks are rapidly increasing their gold reserves-now nearly 20% of global assets. With rising demand and geopolitical pressure, U.S. gold supply is becoming more strategic than ever.
Financials
| Curr Year EPS Estimate | 4.51 |
| Next Quarter EPS Estimate | 0.94 |
| Profit Margin | 22.98% |
| Operating Margin | 24.88 |
| Return on Assets | 0.05 |
| Return on Equity | 0.09 |
| Revenue | 43.2B |
| Earnings Per Share | 3.01 |
| Revenue Per Share | 18.66 |
| Gross Profit | 33,072,001,024 |
| Quarterly Revenue Growth | -0.07 |
General
| Name | Sanofi ADR |
| Ticker | SNY |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Currency | USD |
| Country | USA |
| Fiscal Year End | December |
| Full Time Employees | 82,878 |
About Sanofi ADR
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab, as well as a strategic alliance with the Department of Health " Abu Dhabi for the development of global vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Dividend
Sanofi ADR pays out a dividend of $2.37 per share, with a dividend yield of 4.78%.
SNY's last dividend payment was made to shareholders on June 12, 2025.
They pay out 66.53% of their earnings out as a dividend.
Recent Dividends
| Jun 12, 2025 | $2.21 |
| Jun 6, 2024 | $2.04 |
DoorDash Posts Mixed Q3, Plans Investment Of 'Several Hundred Million Dollars' In 2026
DoorDash plans to invest "several hundred million dollars" in 2026. This will weigh on margins, but it's worth it, analysts argue.
Can Solana Do What Bitcoin Can't? Amplify's New ETF Aims For 36% Income
Amplify ETFs, the issuer known for thematic and income-driven fund products, has just launched the Amplify Solana 3% Monthly Option Income ETF (BATS:SOLM), a first-of-its-kind product combining the growth momentum in Solana (CRYPTO:
A Tiny Biotech Just Posted 10× Stronger Cancer Results - Ad
Early studies show this breakthrough delivery platform would make cancer treatments safer and more powerful. Now, with Big Pharma watching closely, investors are starting to take notice of what could be the next major biotech story.
What to know about 10% reduction in flights at U.S. airports caused by the government shutdown
NEW YORK (AP) — are among those facing 10% reductions in air traffic Friday due to the .
Alibaba AI Crushes Rivals In Crypto Trading, Matches GPT-5 In Math
Alibaba accelerates efforts to unlock value through AI and tech expansion. Qwen3-Max outperforms rivals in crypto trading.
The $43B Big Pharma Story is Starting Over-With a New Player - Ad
Big Pharma once paid $43B for a small biotech with a similar platform. Now, a new company is following that same playbook, leveraging its patented delivery technology to attract partnerships and near-term revenue potential.
IRS Direct File won't be available next year. Here's what that means for taxpayers
WASHINGTON (AP) — IRS Direct File, the electronic system for filing tax returns for free, will not be offered next year, the Trump administration has confirmed.
Anthony Scaramucci Calls Zohran Mamdani's Win An 'Anger-Based Reaction' To Boomer Policies, Says New NYC Mayor Could Become 'Popular' If...
Anthony Scaramucci, the founder of SkyBridge Capital, described Zohran Mamdani’s victory in New York City's mayoral race as an “anger-based reaction” by the young people against the policies of the boomer generation's political elites.
Trump's Next Ban - Coming January 19, 2026 (shocking) - Ad
On Jan 19, 2026, Trump is expected to sign an order banning exports of a material every tech firm needs. Not chips-but without it, tech stops. It's his move for U.S. tech dominance. $2T already committed by giants like Apple and NVIDIA. Weeks remain to position before the shift.
France threatens to block Shein over sale of childlike sex dolls ahead of Paris store opening
PARIS (AP) — French authorities have warned they may block access to after it emerged that the online fast fashion giant had been selling sex dolls with a childlike appearance.
Hedera Gets Its First ETF: Canary's HBAR Fund Lets Investors Tap Into The Tokenization Boom
Canary Capital Group’s new fund, the Canary HBAR ETF (NASDAQ:HBR), launched on Oct 28, marking a significant expansion of investors’ access to digital assets outside of Bitcoin and Ethereum.
The Tesla Shock Nobody Sees Coming - Ad
While headlines scream "Tesla is doomed"...Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as January 29.
Elon Musk Tells Joe Rogan: 'Trump Actually Is Not Perfect, but He's Not Evil'
In a Friday appearance on The Joe Rogan Podcast, Elon Musk defended President Donald Trump, stating that while Trump is "not perfect," he is also "not evil."
Coeur Mining's $7 Billion Deal For New Gold Creates $20 Billion Powerhouse
Coeur Mining Inc. (CDE) announced acquisition of New Gold Inc. (NGD) in all-stock deal valued at $7 billion.
From Ore to Gold Bars-This Nevada Mine Is Already Producing - Ad
Most juniors explore...Few actually produce. This one's already pouring gold thanks to infrastructure that would cost tens of millions to build today. With major land holdings and room to scale, it's one to watch.
IREN Skyrockets After Sealing $9.7 Billion AI Cloud Deal With Microsoft
Pre-market trading sees IREN shares up after securing $9.7B cloud contract with Microsoft, partnering with Dell.
Why Is Phio Pharmaceuticals Stock Soaring Today?
Shares of Phio Pharmaceuticals Corp. (NASDAQ: PHIO) are rising Monday after the company provided an update on an ongoing medical trial.
Gold Bars Are Pouring, but This Miner is Still Priced Like a Startup - Ad
You'd expect a gold miner with production, a full refinery, and big-name investors to be trading at a premium. But this one? It's still under $1
Zohran Mamdani's Historic Victory Earns Him Congratulations From Bill Ackman, Bernie Sanders — Trump Wasn't 'On The Ballot,' Says President
Democrats win high-profile races despite Trump's absence and shutdown. Zohran Mamdani elected NYC mayor, Abigail Spanberger wins VA governorship, Mikie Sherrill flips NJ.
OpenAI and Amazon sign $38B deal for AI computing power
SEATTLE (AP) — OpenAI and Amazon have signed a $38 billion deal that enables the ChatGPT maker to run its artificial intelligence systems on Amazon's cloud computing services.
Is Big Pharma's Next Target Already in Play? - Ad
A small biotech may have cracked one of medicine's biggest problems-how to deliver cancer drugs safely and effectively. With patented technology and promising early data, it's already catching the attention of Big Pharma.
Zohran Mamdani Wins NYC Mayor Race, Abigail Spanberger Becomes Virginia's First Female Governor In Historic Democratic Win (UPDATED)
U.S. stock futures slipped on election night as Democrat Abigail Spanberger made history by becoming Virginia's first female governor, signaling a major political shift while markets reacted to post-election uncertainty.
Japanese game maker Nintendo reports zooming sales and profit on its hit Switch 2 machine
TOKYO (AP) — Japanese video-game maker Nintendo’s net profit jumped 85% in April-September from the year before, as its sales more than doubled following the launch of its hit Switch 2 console in June, the company said Tuesday.
"Tech Prophet" Who Predicted the iPhone Now Predicts... - Ad
George Gilder - who predicted the iPhone 17 years early and gave Reagan the first microchip - is making his boldest call yet. He says an American nanotech "super-convergence" could mint more millionaires than any event in recent memory. He's found 3 stocks set to benefit before November 18's bombshell.
Pizza Hut's parent company says it's considering selling the chain
Pizza Hut could soon be up for sale.
Why Did MediciNova Stock (MNOV) Jump Over 87% In After-Hours Trading?
MediciNova shares soared over 87% in after-hours trading on Thursday following the publication of promising research.
Why Are 21 Billionaires Moving Their Money ASAP? - Ad
One of the biggest stock market events in 25 years is rapidly unfolding... The economist who predicted the 2008 Financial Crisis says it will be: "The Biggest Crash of Our Lifetime." Starting November 19 it could cut the entire tech marketing by HALF.
Elon Musk Calls Out Sam Altman Over Tesla Roadster Refund: 'This Issue Was Fixed and You Received a Refund Within 24 Hours'
Elon Musk and Sam Altman are once again in a public spat, this time over a car.
Terns Pharmaceuticals' Leukemia Drug Seen As Potential Disruptor In CML Treatment Landscape, Analyst Upgrades
Terns Pharmaceuticals shares rise after TERN-701 shows a 75% response rate in the CML trial, and William Blair upgrades the stock to Outperform.
Central Banks Are Buying More Gold Than Ever-And This U.S. Miner Is Ready to Oblige - Ad
Central banks are rapidly increasing their gold reserves-now nearly 20% of global assets. With rising demand and geopolitical pressure, U.S. gold supply is becoming more strategic than ever.
Japan's Toyota, hurt by President Trump's tariffs, reports a drop in profit
TOKYO (AP) — Toyota reported a 7% year-on-year drop in its profit for April-September on Wednesday, as President Donald Trump’s tariffs slammed Japanese automakers, but it raised its forecast for the full fiscal year.
What to know as the annual sign-up window for health insurance arrives
Higher prices, less help and all hang over health insurance markets as shoppers start looking for coverage this week.
A Tiny Biotech Just Posted 10× Stronger Cancer Results - Ad
Early studies show this breakthrough delivery platform would make cancer treatments safer and more powerful. Now, with Big Pharma watching closely, investors are starting to take notice of what could be the next major biotech story.
Norway transport firm steps up controls after tests show Chinese-made buses can be halted remotely
OSLO, Norway (AP) — A leading Norwegian public transport operator has said it will introduce stricter security requirements and step up anti-hacking measures after a test on new Chinese-made electric buses showed the manufacturer could remotely turn them off.
Apple Planning A Chromebook Killer? iPhone-Maker's New Budget Mac Will Target Students, Businesses And Casual Users: Report
Apple is reportedly developing a new budget Mac laptop aimed at students, businesses and casual users, targeting Chromebook and entry-level Windows PC buyers with a planned 2026 launch.
The $43B Big Pharma Story is Starting Over-With a New Player - Ad
Big Pharma once paid $43B for a small biotech with a similar platform. Now, a new company is following that same playbook, leveraging its patented delivery technology to attract partnerships and near-term revenue potential.
Taylor Swift, Elon Musk, Donald Trump, MrBeast — Robinhood Just Made Their Mojo Tradable
Robinhood has new prediction markets for its customers, with a focus on the entertainment sector. Here are some of the new markets.
Why Are First Solar Shares Surging On Friday?
First Solar beats Q3 sales estimates and reports record module shipments. Analyst raises price target to $150 despite supply chain challenges.
Trump's Next Ban - Coming January 19, 2026 (shocking) - Ad
On Jan 19, 2026, Trump is expected to sign an order banning exports of a material every tech firm needs. Not chips-but without it, tech stops. It's his move for U.S. tech dominance. $2T already committed by giants like Apple and NVIDIA. Weeks remain to position before the shift.
Trump tariffs face Supreme Court test in trillion-dollar test of executive power
WASHINGTON (AP) — President power to unilaterally impose far-reaching is coming before the Supreme Court on Wednesday in a pivotal test of executive power with trillion-dollar implications for the global economy.
Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.